Sonoma Pharmaceuticals Reports Recent Publication from Australia Highlighting Potential for Microdox in Managing Urinary Tract Infections
- None.
- None.
The recent publication on the use of Microdox in managing urinary tract infections in children with bladder dysfunction presents a noteworthy advancement in pediatric urology. Microdox's active ingredient, hypochlorous acid, is known for its antimicrobial properties, which are particularly vital in reducing healthcare-associated infections. The study's focus on children with neurogenic or non-neurogenic bladder dysfunction is significant because these patients are at an increased risk for recurrent UTIs and subsequent kidney damage, a concern for healthcare providers and parents alike.
Bladder irrigation with Microdox could potentially decrease the frequency of antibiotic use, thereby mitigating the risk of antibiotic resistance, which is a growing global health concern. The publication's suggestion for multi-center trials to validate long-term preventative effects is a prudent step in the research process and could lead to a paradigm shift in UTI management if the results are positive. The implications for Sonoma Pharmaceuticals are considerable, as successful trials could expand the applications of their Microcyn technology and potentially increase market share in pediatric care solutions.
UTIs in children, particularly those with bladder dysfunction, represent a complex clinical challenge. The conventional treatment often involves antibiotics, which can lead to overuse and resistance. The approach of using Microdox for bladder irrigation is intriguing, as it offers a non-antibiotic alternative that could prevent infections while preserving the child's native flora. This could be especially beneficial for children requiring clean intermittent catheterization, a group particularly susceptible to UTIs.
From a clinical perspective, the safety profile of Microdox, as mentioned in the publication, with no adverse effects reported in the short term, is promising. However, it is essential to consider the practicality of implementing such a treatment regimen in a routine clinical setting. The ease of use, cost-effectiveness and patient compliance will be important factors in determining its feasibility as a standard care practice. If proven effective in long-term studies, this treatment could substantially improve the quality of life for these children and potentially reduce healthcare costs associated with managing chronic UTIs.
The economic implications of introducing an alternative UTI management solution like Microdox are multifaceted. On one hand, if the clinical trials confirm its efficacy and safety, it could lead to a reduction in hospitalizations and medical interventions for children with recurrent UTIs, translating to significant cost savings for the healthcare system. On the other hand, the initial investment in clinical trials and subsequent marketing efforts to promote this new application of Microcyn technology could be substantial for Sonoma Pharmaceuticals.
Moreover, the adoption of Microdox in clinical practice hinges on its cost-effectiveness compared to existing treatments. The potential reduction in antibiotic prescriptions could also have a positive economic impact by slowing the progression of antibiotic resistance, which is a considerable cost driver in healthcare. In the long run, if Microdox becomes a standard treatment, it could lead to a more sustainable healthcare model with fewer complications from UTIs and antibiotic resistance.
BOULDER, CO / ACCESSWIRE / April 4, 2024 / Sonoma Pharmaceuticals, Inc. (NASDAQ:SNOA), a global healthcare leader developing and producing patented Microcyn® technology based stabilized hypochlorous acid (HOCl) products for a wide range of applications, including wound, eye, oral and nasal care, dermatological conditions and podiatry, reported a recent publication in the journal Neurourology and Urodynamics highlighting the potential for Microdox® in the management of urinary tract infections, or UTIs, in children with neurogenic or non‐neurogenic bladder dysfunction.[1]
Microdox is a super-oxidized solution based on Sonoma's patented Microcyn technology intended to treat and prevent infections in the urinary tract and bladder. Microdox is licensed by the Therapeutic Goods Administration in Australia and by Medsafe in New Zealand for the prevention and treatment of UTIs, and is currently available in these countries through Sonoma's partner, Te Arai BioFarma Ltd.
The publication in Neurourology and Urodynamics notes that children with a neurogenic bladder are at risk of developing recurrent urinary tract infections and long‐term kidney failure, and that due to an altered lower urinary tract, children may be overtreated for simple bacteriuria, or undertreated for a potentially severe urinary tract infection.
The authors posit that this risk necessitates new approaches to UTI management in these patients, who are high users of healthcare and for whom UTIs are a significant health burden. They propose that bladder irrigation with electrochemically activated solutions, such as Microdox, could be a powerful therapeutic option in children who require clean intermittent catheterization, with the potential to significantly approve outcomes for these patients.
The article cites evidence from recent clinical trials that, in the short term at least, electrochemically activated solutions are effective in safely preventing asymptomatic bacteriuria with no adverse effects. The authors conclude that multi‐center trials will be required to establish potential long‐term preventative effects.
"We are pleased that research continues into the potential for Microdox to reduce urinary tract infections in additional patient groups," remarked Amy Trombly, CEO of Sonoma Pharmaceuticals. "Our goal at Sonoma is to improve the quality of life for as many patients as possible, and we look forward the results of future clinical trials of this important application of our Microcyn technology."
About Sonoma Pharmaceuticals, Inc.
Sonoma Pharmaceuticals is a global healthcare leader for developing and producing stabilized hypochlorous acid (HOCl) products for a wide range of applications, including wound, eye, oral and nasal care, dermatological conditions, podiatry, animal health care and non-toxic disinfectants. Sonoma's products are clinically proven to reduce itch, pain, scarring, and irritation safely and without damaging healthy tissue. In-vitro and clinical studies of HOCl show it to safely manage skin abrasions, lacerations, minor irritations, cuts, and intact skin. Sonoma's products are sold either directly or via partners in 55 countries worldwide and the company actively seeks new distribution partners. The company's principal office is in Boulder, Colorado, with manufacturing operations in Guadalajara, Mexico. European marketing and sales are headquartered in Roermond, Netherlands. More information can be found at www.sonomapharma.com. For partnership opportunities, please contact busdev@sonomapharma.com.
About Te Arai BioFarma Ltd.
Te Arai BioFarma Limited is a privately owned New Zealand and Australian company specializing in medical devices and specialty medicines. We aim to improve health and productivity through the affordable control and prevention of disease. Te Arai BioFarma is committed to maintaining long term collaborative and innovative relationships with significant global suppliers of health products. Through partnering with leading suppliers both locally and internationally, Te Arai BioFarma is committed to ensuring the highest standard of care is taken in bringing products from these suppliers to Australasia. More information can be found at https://www.tearaibiofarma.com.au/microdox.
Forward-Looking Statements
Except for historical information herein, matters set forth in this press release are forward-looking within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995, including statements about the commercial and technology progress and future financial performance of Sonoma Pharmaceuticals, Inc. and its subsidiaries (the "company"). These forward-looking statements are identified by the use of words such as "continue," "develop," "anticipate," "expect" and "expand," among others. Forward-looking statements in this press release are subject to certain risks and uncertainties inherent in the company's business that could cause actual results to vary, including such risks that regulatory clinical and guideline developments may change, scientific data may not be sufficient to meet regulatory standards or receipt of required regulatory clearances or approvals, clinical results may not be replicated in actual patient settings, protection offered by the company's patents and patent applications may be challenged, invalidated or circumvented by its competitors, the available market for the company's products will not be as large as expected, the company's products will not be able to penetrate one or more targeted markets, revenues will not be sufficient to meet the company's cash needs, fund further development, as well as uncertainties relative to the COVID-19 pandemic and economic development, varying product formulations and a multitude of diverse regulatory and marketing requirements in different countries and municipalities, and other risks detailed from time to time in the company's filings with the Securities and Exchange Commission. The company disclaims any obligation to update these forward-looking statements, except as required by law.
Sonoma Pharmaceuticals™, Microcyn® and Microdox® are trademarks or registered trademarks of Sonoma Pharmaceuticals, Inc. All other trademarks and service marks are the property of their respective owners.
[1] Singh G‐K, Deshpande A, Schlegel G, Starkey M, Taghavi K. The rationale for bladder washouts in children with neurogenic bladder. Neurourol Urodyn. 2024;1‐6. doi:10.1002/nau.25450
SOURCE: Sonoma Pharmaceuticals, Inc.
View the original press release on accesswire.com
